Suppr超能文献

前列腺癌的医学管理新进展。

New developments in the medical management of prostate cancer.

机构信息

Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

出版信息

Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442.

Abstract

Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.

摘要

前列腺癌是美国重大的公共卫生负担,也是导致癌症发病率和死亡率的主要原因,尽管在此前十年中观察到前列腺癌特异性死亡率呈下降趋势。尽管目前尚不清楚这种积极趋势的原因,但可能有多种因素共同作用。本更新将根据目前对前列腺癌生物学的理解,回顾正在进行的研究进展,并总结前列腺癌治疗方面的治疗进展。本综述的文献资料于 2009 年通过在 PubMed 上搜索以下关键词进行选择:前列腺肿瘤,去势,雄激素受体,激素和化疗。重点是过去 5 到 10 年中晚期前列腺癌治疗的已发表临床研究。本综述还包括目前正在开发用于治疗晚期前列腺癌的针对雄激素受体的新型激素药物。

相似文献

1
New developments in the medical management of prostate cancer.
Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442.
2
[The treatment of castration-resistant prostate cancer].
Magy Onkol. 2012 Dec;56(4):219-28. Epub 2012 Oct 3.
3
The utility of prostate-specific antigen in the management of advanced prostate cancer.
BJU Int. 2013 Sep;112(5):548-60. doi: 10.1111/bju.12061. Epub 2013 Jul 4.
6
Overcoming castration resistance in prostate cancer.
Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b.
7
Treatment options in hormone-refractory prostate cancer: current and future approaches.
Drugs. 2001;61(15):2177-92. doi: 10.2165/00003495-200161150-00003.
8
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3.
9
Novel concepts in androgen receptor blockade.
Cancer J. 2008 Jan-Feb;14(1):11-4. doi: 10.1097/PPO.0b013e318161d13e.
10
[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7.

引用本文的文献

2
Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.
Cancers (Basel). 2020 Aug 27;12(9):2428. doi: 10.3390/cancers12092428.
3
[Citron Rho-interacting serine/threonine kinase knockdown suppresses prostate cancer cell proliferation and metastasis by blocking Hippo-YAP pathway].
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Mar 30;39(3):257-263. doi: 10.12122/j.issn.1673-4254.2019.03.01.
5
Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells.
EBioMedicine. 2019 Apr;42:397-407. doi: 10.1016/j.ebiom.2019.03.032. Epub 2019 Mar 21.
6
Targeting DNA Methyltranferases in Urological Tumors.
Front Pharmacol. 2018 Apr 13;9:366. doi: 10.3389/fphar.2018.00366. eCollection 2018.
7
Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Cancer Res. 2018 Jun 15;78(12):3147-3162. doi: 10.1158/0008-5472.CAN-17-3006. Epub 2018 Apr 26.
9
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.
J Manag Care Spec Pharm. 2017 Feb;23(2):225-235. doi: 10.18553/jmcp.2016.16233. Epub 2016 Dec 7.
10
Epigenetic modulators as therapeutic targets in prostate cancer.
Clin Epigenetics. 2016 Sep 15;8:98. doi: 10.1186/s13148-016-0264-8. eCollection 2016.

本文引用的文献

1
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.
2
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.
3
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.
4
Screening and prostate-cancer mortality in a randomized European study.
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
5
Mortality results from a randomized prostate-cancer screening trial.
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
6
CYP17 inhibition as a hormonal strategy for prostate cancer.
Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237.
7
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54. doi: 10.1093/jnci/djn255. Epub 2008 Aug 11.
9
Targeting CYP17: established and novel approaches in prostate cancer.
Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验